Suppression of TG-interacting factor sensitizes arsenic trioxide-induced apoptosis in human hepatocellular carcinoma cells

Biochemical Journal

Volumn 438, Issue 2, 2011, Pages 349-358

  Liu, Zi Miao ^a   Tseng, Joseph T ^b   Hong, Duang Yang ^a   Huang, Huei Sheng ^a  

^a NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^b NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

Author keywords

Akt; Arsenic trioxide; Hepatocellular carcinoma; Human antigen R (HuR); TG interacting factor (TGIF); Transforming growth factor (TGF )

Indexed keywords

ARSENIC TRIOXIDE; BIOTIN; CYCLIN DEPENDENT KINASE INHIBITOR 1; EPIDERMAL GROWTH FACTOR RECEPTOR; HOMEODOMAIN PROTEIN; MESSENGER RNA; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; SMAD PROTEIN; TG INTERACTING FACTOR; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG;

3' UNTRANSLATED REGION; APOPTOSIS; ARTICLE; DOWN REGULATION; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; LIVER CELL CARCINOMA; PRIORITY JOURNAL; PROTEIN DEGRADATION; RNA PROBE; TRANSCRIPTION REGULATION;

3' UNTRANSLATED REGIONS; ANTIGENS, SURFACE; APOPTOSIS; ARSENICALS; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CYCLIN-DEPENDENT KINASE INHIBITOR P21; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; HOMEODOMAIN PROTEINS; HUMANS; LIVER NEOPLASMS; MODELS, BIOLOGICAL; OXIDES; PHOSPHATIDYLINOSITOL 3-KINASES; RECEPTOR, EPIDERMAL GROWTH FACTOR; REPRESSOR PROTEINS; RNA STABILITY; RNA, MESSENGER; RNA-BINDING PROTEINS; SIGNAL TRANSDUCTION; TRANSCRIPTION, GENETIC; TRANSFORMING GROWTH FACTOR BETA;

EID: 80051704370     PISSN: 02646021     EISSN: 14708728     Source Type: Journal    
DOI: 10.1042/BJ20101653     Document Type: Article

References (52)

1. Miller, Jr, W. H., Schipper, H. M., Lee, J. S., Singer, J. and Waxman, S. (2002) Mechanisms of action of arsenic trioxide. Cancer Res. 62, 3893-3903 (Pubitemid 34792653)
2. Douer, D. and Tallman, M. S. (2005) Arsenic trioxide: new clinical experience with an old medication in hematologic malignancies. J. Clin. Oncol. 23, 2396-2410 (Pubitemid 46218734)
3. Dilda, P. J. and Hogg, P. J. (2007) Arsenical-based cancer drugs. Cancer Treat. Rev. 33, 542-564 (Pubitemid 47355338)
4. Platanias, L. C. (2009) Biological responses to arsenic compounds. J. Biol. Chem. 284, 18583-18587
5. Jemal, A., Siegel, R., Ward, E., Hao, Y., Xu, J., Murray, T. and Thun, M. J. (2008) Cancer statistics, 2008. CA Cancer J. Clin. 58, 71-96 (Pubitemid 351521864)
6. Thomas, M. (2009) Molecular targeted therapy for hepatocellular carcinoma. J. Gastroenterol. 44 (Suppl. 19), 136-141
7. Lin, C. C., Hsu, C., Hsu, C. H., Hsu, W. L., Cheng, A. L. and Yang, C. H. (2007) Arsenic trioxide in patients with hepatocellular carcinoma: a phase II trial. Invest. New Drugs 25, 77-84 (Pubitemid 44657646)
8. Ramos, A. M., Fernandez, C., Amran, D., Sancho, P., de Blas, E. and Aller, P. (2005) Pharmacologic inhibitors of PI3K/Akt potentiate the apoptotic action of the antileukemic drug arsenic trioxide via glutathione depletion and increased peroxide accumulation in myeloid leukemia cells. Blood 105, 4013-4020 (Pubitemid 40656150)
9. Huang, H. S., Liu, Z. M. and Hong, D. Y. (2010) Blockage of JNK pathway enhances arsenic trioxide-induced apoptosis in human keratinocytes. Toxicol. Appl. Pharmacol. 244, 234-241
10. WAF1/CIP1 expression in human epidermoid carcinoma A431 cells. Cell. Signalling 18, 244-255
11. WAF1/CIP1 activation involved in the arsenic trioxide-induced human epidermoid carcinoma A431 cellular cytotoxicity. J. Biomed. Sci. 13, 113-125
12. WAF1/CIP1 expression. J. Biomed. Sci. 15, 333-342
13. Wotton, D. and Massague, J. (2001) Smad transcriptional corepressors in TGFβ family signaling. Curr. Top. Microbiol. Immunol. 254, 145-164
14. Gripp, K. W., Wotton, D., Edwards, M. C., Roessler, E., Ades, L., Meinecke, P., Richieri-Costa, A., Zackai, E. H., Massague, J., Muenke, M. and Elledge, S. J. (2000) Mutations in TGIF cause holoprosencephaly and link NODAL signalling to human neural axis determination. Nat. Genet. 25, 205-208 (Pubitemid 30394994)
15. Derynck, R., Akhurst, R. J. and Balmain, A. (2001) TGF-β signaling in tumor suppression and cancer progression. Nat. Genet. 29, 117-129 (Pubitemid 32952643)
16. Pardali, K. and Moustakas, A. (2007) Actions of TGF-β as tumor suppressor and pro-metastatic factor in human cancer. Biochim. Biophys. Acta 1775, 21-62 (Pubitemid 44881193)
17. WAF1/Cip1 gene by acting as a superactivator of the ubiquitous transcription factor Sp1. J. Biol. Chem. 274, 29572-29581
18. Senturk, S., Mumcuoglu, M., Gursoy-Yuzugullu, O., Cingoz, B., Akcali, K. C. and Ozturk, M. (2010) Transforming growth factor-β induces senescence in hepatocellular carcinoma cells and inhibits tumor growth. Hepatology 52, 966-974
19. Borlak, J., Meier, T., Halter, R., Spanel, R. and Spanel-Borowski, K. (2005) Epidermal growth factor-induced hepatocellular carcinoma: gene expression profiles in precursor lesions, early stage and solitary tumours. Oncogene 24, 1809-1819 (Pubitemid 40462784)
20. Lo, R. S., Wotton, D. and Massague, J. (2001) Epidermal growth factor signaling via Ras controls the Smad transcriptional co-repressor TGIF. EMBO J. 20, 128-136 (Pubitemid 32099109)
21. Yang, S., Nugent, M. A. and Panchenko, M. P. (2008) EGF antagonizes TGF-β-induced tropoelastin expression in lung fibroblasts via stabilization of Smad corepressor TGIF. Am. J. Physiol. Lung Cell. Mol. Physiol. 295, L143-151
22. Horie, T., Ono, K., Kinoshita, M., Nishi, H., Nagao, K., Kawamura, T., Abe, Y., Wada, H., Shimatsu, A., Kita, T. and Hasegawa, K. (2008) TG-interacting factor is required for the differentiation of preadipocytes. J. Lipid Res. 49, 1224-1234
23. Huang, H. S., Chang, W. C. and Chen, C. J. (2002) Involvement of reactive oxygen species in arsenite-induced downregulation of phospholipid hydroperoxide glutathione peroxidase in human epidermoid carcinoma A431 cells. Free Radical Biol. Med. 33, 864-873 (Pubitemid 35232321)
24. Massague, J. (2008) TGFβ in cancer. Cell 134, 215-230
25. Hamid, R., Patterson, J. and Brandt, S. J. (2008) Genomic structure, alternative splicing and expression of TG-interacting factor, in human myeloid leukemia blasts and cell lines. Biochim. Biophys. Acta 1779, 347-355 (Pubitemid 351662711)
26. Westmark, C. J., Bartleson, V. B. and Malter, J. S. (2005) RhoB mRNA is stabilized by HuR after UV light. Oncogene 24, 502-511 (Pubitemid 40188597)
27. Masuda, K., Abdelmohsen, K. and Gorospe, M. (2009) RNA-binding proteins implicated in the hypoxic response. J. Cell. Mol. Med. 13, 2759-2769
28. Datta, S. R., Brunet, A. and Greenberg, M. E. (1999) Cellular survival: a play in three Akts. Genes Dev. 13, 2905-2927
29. Tabellini, G., Cappellini, A., Tazzari, P. L., Fala, F., Billi, A. M., Manzoli, L., Cocco, L. and Martelli, A. M. (2005) Phosphoinositide 3-kinase/Akt involvement in arsenic trioxide resistance of human leukemia cells. J. Cell. Physiol. 202, 623-634 (Pubitemid 40041333)
30. Kang, S. H., Song, J. H., Kang, H. K., Kang, J. H., Kim, S. J., Kang, H. W., Lee, Y. K. and Park, D. B. (2003) Arsenic trioxide-induced apoptosis is independent of stress-responsive signaling pathways but sensitive to inhibition of inducible nitric oxide synthase in HepG2 cells. Exp. Mol. Med. 35, 83-90
31. Tian, C., Gao, P., Zheng, Y., Yue, W., Wang, X., Jin, H. and Chen, Q. (2008) Redox status of thioredoxin-1 (TRX1) determines the sensitivity of human liver carcinoma cells (HepG2) to arsenic trioxide-induced cell death. Cell Res. 18, 458-471 (Pubitemid 351498853)
32. Fei, M., Lu, M., Wang, Y., Zhao, Y., He, S., Gao, S., Ke, Q., Liu, Y., Li, P., Cui, X. et al. (2009) Arsenic trioxide-induced growth arrest of human hepatocellular carcinoma cells involving FOXO3a expression and localization. Med. Oncol. 26, 178-185
33. Roboz, G. J., Dias, S., Lam, G., Lane, W. J., Soignet, S. L., Warrell, Jr, R. P. and Rafii, S. (2000) Arsenic trioxide induces dose- and time-dependent apoptosis of endothelium and may exert an antileukemic effect via inhibition of angiogenesis. Blood 96, 1525-1530
34. Xiao, Y. F., Liu, S. X., Wu, D. D., Chen, X. and Ren, L. F. (2006) Inhibitory effect of arsenic trioxide on angiogenesis and expression of vascular endothelial growth factor in gastric cancer. World J. Gastroenterol. 12, 5780-5786 (Pubitemid 44594244)
35. Cavigelli, M., Li, W. W., Lin, A., Su, B., Yoshioka, K. and Karin, M. (1996) The tumor promoter arsenite stimulates AP-1 activity by inhibiting a JNK phosphatase. EMBO J. 15, 6269-6279 (Pubitemid 26397900)
36. Richter, J., Beffa, L., Wagner, U., Schraml, P., Gasser, T. C., Moch, H., Mihatsch, M. J. and Sauter, G. (1998) Patterns of chromosomal imbalances in advanced urinary bladder cancer detected by comparative genomic hybridization. Am. J. Pathol. 153, 1615-1621 (Pubitemid 28509919)
37. Nakakuki, K., Imoto, I., Pimkhaokham, A., Fukuda, Y., Shimada, Y., Imamura, M., Amagasa, T. and Inazawa, J. (2002) Novel targets for the 18p11.3 amplification frequently observed in esophageal squamous cell carcinomas. Carcinogenesis 23, 19-24 (Pubitemid 34213547)
38. Wotton, D., Lo, R. S., Lee, S. and Massague, J. (1999) A Smad transcriptional corepressor. Cell 97, 29-39 (Pubitemid 29165887)
39. Fiorentino, M., Altimari, A., D'Errico, A., Cukor, B., Barozzi, C., Loda, M. and Grigioni, W. F. (2000) Acquired expression of p27 is a favorable prognostic indicator in patients with hepatocellular carcinoma. Clin. Cancer Res. 6, 3966-3972
40. Calvisi, D. F., Ladu, S., Pinna, F., Frau, M., Tomasi, M. L., Sini, M., Simile, M. M., Bonelli, P., Muroni, M. R., Seddaiu, M. A. et al. (2009) SKP2 and CKS1 promote degradation of cell cycle regulators and are associated with hepatocellular carcinoma prognosis. Gastroenterology 137, 1816-1826 e1811-1810
41. Seo, S. R., Lallemand, F., Ferrand, N., Pessah, M., L'Hoste, S., Camonis, J. and Atfi, A. (2004) The novel E3 ubiquitin ligase Tiul1 associates with TGIF to target Smad2 for degradation. EMBO J. 23, 3780-3792 (Pubitemid 39389709)
42. Lin, H. K., Bergmann, S. and Pandolfi, P. P. (2004) Cytoplasmic PML function in TGF-β signalling. Nature 431, 205-211 (Pubitemid 39243475)
43. Zhang, Y., Bhatia, D., Xia, H., Castranova, V., Shi, X. and Chen, F. (2006) Nucleolin links to arsenic-induced stabilization of GADD45α mRNA. Nucleic Acids Res. 34, 485-495 (Pubitemid 43245430)
44. Campos, A. R., Grossman, D. and White, K. (1985) Mutant alleles at the locus elav in Drosophila melanogaster lead to nervous system defects. A developmental-genetic analysis. J. Neurogenet. 2, 197-218 (Pubitemid 15042714)
45. Good, P. J. (1995) A conserved family of elav-like genes in vertebrates. Proc. Natl. Acad. Sci. U.S.A. 92, 4557-4561
46. Lal, A., Kawai, T., Yang, X., Mazan-Mamczarz, K. and Gorospe, M. (2005) Antiapoptotic function of RNA-binding protein HuR effected through prothymosin α. EMBO J. 24, 1852-1862 (Pubitemid 40769504)
47. Abdelmohsen, K., Lal, A., Kim, H. H. and Gorospe, M. (2007) Posttranscriptional orchestration of an anti-apoptotic program by HuR. Cell Cycle 6, 1288-1292 (Pubitemid 47327958)
48. Mei, C., Sun, L., Liu, Y., Yang, Y., Cai, X., Liu, M., Yao, W., Wang, C., Li, X., Wang, L. et al. (2010) Transcriptional and post-transcriptional control of DNA methyltransferase 3B is regulated by phosphatidylinositol 3 kinase/Akt pathway in human hepatocellular carcinoma cell lines. J. Cell. Biochem. 111, 158-167
49. Vara, J. A., Casado, E., de Castro, J., Cejas, P., Belda-Iniesta, C. and Gonzalez-Baron, M. (2004) PI3K/Akt signalling pathway and cancer. Cancer Treat. Rev. 30, 193-204
50. Altman, J. K., Yoon, P., Katsoulidis, E., Kroczynska, B., Sassano, A., Redig, A. J., Glaser, H., Jordan, A., Tallman, M. S., Hay, N. and Platanias, L. C. (2008) Regulatory effects of mammalian target of rapamycin-mediated signals in the generation of arsenic trioxide responses. J. Biol. Chem. 283, 1992-2001
51. Li, Y., Qu, X., Qu, J., Zhang, Y., Liu, J., Teng, Y., Hu, X., Hou, K. and Liu, Y. (2009) Arsenic trioxide induces apoptosis and G2/M phase arrest by inducing Cbl to inhibit PI3K/Akt signaling and thereby regulate p53 activation. Cancer Lett. 284, 208-215
52. Frohlich, E., Czarnocka, B., Brossart, P. and Wahl, R. (2008) Antitumor effects of arsenic trioxide in transformed human thyroid cells. Thyroid 18, 1183-1193